FUTONG TECH (00465) announced its interim results, reporting a loss attributable to shareholders of 34.836 million yuan, an increase of 6.54% year-on-year.

20:35 27/08/2026

Futong Technology (00465) announced its interim results for the six months ending June 30, 2026. The group achieved a revenue of 43.653 million yuan, representing a year-on-year decrease of 25.1%; the loss attributable to shareholders amounted to 34.836 million yuan, an increase of 6.54% year-on-year; the loss per share was 0.11 yuan.

FUTONG TECH (00465) announced its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 43.653 million, a decrease of 25.1% year-on-year; the loss attributable to the company's owners amounted to RMB 34.836 million, an increase of 6.54% year-on-year; the loss per share was RMB 0.11. As the transformation of enterprise-level clients in the Chinese market deepens in digital applications and the IT market continues to evolve, the Group is actively providing enterprise management services to its clients, including two major businesses: Cloud Intelligence and Data Intelligence. During the six months ended June 30, 2026 (the Period), the Group further focused on digital products and upgraded solutions driven by cloud computing and AI, while reducing traditional integration business, resulting in an overall revenue decline of approximately 25%.

MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.

AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.

AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.